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Background. Causes of thrombocytopenia range from laboratory errors to life-threatening pathological conditions. To establish the cause, 
appropriate laboratory investigation is required.
Objectives. To determine the prevalence and causes of platelet counts <100 × 109/L in state health facilities in Johannesburg, South Africa, 
as well as the quality of the subsequent laboratory work-up in this setting.
Methods. Full blood counts (FBCs) performed on 7 randomly selected days at the National Health Laboratory Service laboratory at Chris 
Hani Baragwanath Academic Hospital were retrospectively reviewed. Samples with platelet counts <100 × 109/L were identified, and 
pertinent information was extracted from the laboratory database.
Results. Of 4 456 FBCs included, 381 (8.6%) had a platelet count of <100 × 109/L. Thrombocytopenia prevalence rates were high in 
haematology/oncology wards (34.4%), intensive care units (20.5%) and medical wards (18.7%) and among neonatal inpatients (16.5%), 
and were lowest in outpatient clinics (1 - 2%). A cause was apparent in ~60% of patients, the commonest causes being chemotherapy 
and sepsis (each comprising >20% of the recognised causes). Spurious thrombocytopenia, disseminated tuberculosis, aplastic anaemia, 
immune thrombocytopenia and malignant marrow infiltration each accounted for 5 - 10% of the causes, while malaria, thrombotic 
thrombocytopenic purpura, HIV effect and liver disease were each identified in <5% of cases. HIV status was documented in ~70% of the 
patients, of whom ~50% tested positive. The quality of the laboratory work-up showed differences between specialties within the hospital 
setting, and was poorest in the primary healthcare clinic sector.
Conclusion. Thrombocytopenia is common in hospitalised patients in the Johannesburg academic state sector. Differences in the quality 
of the laboratory work-up emphasise the need for a standardised approach to thrombocytopenia investigation and increased awareness 
among clinicians.
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The full blood count (FBC) is among the most 
frequently requested laboratory tests, and a low platelet 
count is a common finding. Thrombocytopenia is 
defined as a platelet count below the normal reference 
range (~150 × 109/L in adults), but is most clinically 
significant when the platelet count is <100 × 109/L.[1] The causes of 
thrombocytopenia range from laboratory errors to life-threatening 
medical emergencies, and appropriate laboratory investigation is 
indicated in its work-up. First-line testing includes a differential white 
cell count and peripheral blood smear microscopy, which serve as 
a guide for further investigation. This could include bone marrow 
aspirate and trephine biopsy examination, exclusion of an underlying 
coagulopathy, and testing for a variety of infections.[1,2] In the South 
African (SA) context, exclusion of HIV infection is particularly 
important, as this may cause thrombocytopenia through several 
mechanisms. These include involvement of the bone marrow by 
opportunistic infections and malignancies and increased incidences of 
immune thrombocytopenia (ITP) and thrombotic thrombocytopenic 
purpura (TTP), as well as impaired platelet production as a result of both 
HIV-associated stromal cell dysfunction[3] and direct HIV infection of 
megakaryocytes.[4] The aims of this study were to determine: (i) the 
prevalence and causes of platelet counts <100 × 109/L in the state sector 
in Johannesburg, SA, with emphasis on the effect of HIV infection; and 
(ii) the adequacy of the subsequent laboratory investigation. For this 
purpose, FBCs performed at the National Health Laboratory Service 
laboratory at Chris Hani Baragwanath Academic Hospital (CHBAH) 
were retrospectively reviewed. This laboratory serves several strata of 
public health services in Soweto, Johannesburg, ranging from over 50 
primary healthcare (PHC) clinics to CHBAH.
Methods
Sample selection and data collection
FBCs performed on 7 non-consecutive days in 2012 were extracted 
from the laboratory information system (DisaLab Version 
04.16.04.373). Sample selection was random, but in order to avoid 
temporal bias with respect to the prevalence or causes identified, 
each day of the week as well as each season of the year were 
equally represented. Samples with platelet counts <100 × 109/L 
were identified, and details available in patients’ laboratory histories 
recorded. These included the clinical history, demographic details, 
evidence of infection (including HIV), presence of a coagulopathy, 
peripheral blood and bone marrow microscopy findings, and the 
results of any other investigations judged to be pertinent. The 
cause for the thrombocytopenia (if apparent) was documented, 
and the adequacy of the laboratory work-up judged in accordance 
with previously published recommendations.[1,2] Peripheral blood 
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smear review was regarded as a minimum essential additional test. 
Investigations for infection-related causes of thrombocytopenia (such 
as bacterial sepsis, viral hepatitis, etc.) were similarly regarded as 
mandatory in cases where a cause was not apparent from either the 
peripheral smear or the clinical history. In the presence of red cell 
fragments on the peripheral smear or any clinical risk factors for 
disseminated intravascular coagulation (DIC) (such as sepsis, trauma, 
etc.), a coagulopathy screen was considered to be indicated (except in 
neonates), and if ITP was the favoured cause for the low platelet count, 
testing for secondary causes (such as an underlying autoimmune 
pathology or viral infection, particularly viral hepatitis) was judged 
necessary. The need for further investigation (such as a bone marrow 
aspirate and trephine biopsy) was judged on a case-by-case basis. 
Analysis was conducted by medical staff (consultants and registrars) 
in the Department of Molecular Medicine and Haematology at the 
University of the Witwatersrand, Johannesburg, and the study was 
approved by the university’s human research ethics committee.
Assessment of work-up adequacy
The thrombocytopenia work-up was considered adequate if the 
cause for the thrombocytopenia was discovered and/or all the 
indicated laboratory investigations were performed. If only some of 
the investigations were performed, the work-up was judged to be 
partially adequate, and if no additional laboratory investigation was 
performed, it was considered inadequate. Although HIV testing is a 
crucial component of thrombocytopenia investigation in SA, this was 
excluded from our analysis of work-up adequacy because it was not 
possible to determine which patients were known to be HIV-positive 
from previous testing at an alternative site.
Statistical analysis
Statistical analysis was performed using Statistica software, version 
12.0 (StatSoft (Pty) Ltd). Continuous data are presented as means 
(standard deviation (SD)) and categorical data as frequencies and 
percentages. Means were compared using Student’s t-test, and cate-
gorical variables using the χ2 statistic or Fisher’s exact test when 
necessary. Multivariate logistic regression was performed to deter-
mine predictors of the presence of a coagulopathy. Data were 
presented as odds ratios (ORs) with 95% confidence intervals (CIs). 
Statistical signiﬁcance was accepted at a two-sided p-value of ≤0.05.
Results
Thrombocytopenia prevalence (TP)
A total of 4 456 FBCs were extracted from the laboratory data-
base, of which 381 (8.6%) had platelet counts <100 × 109/L. The 
registered patient locations included inpatient, outpatient and 
casualty facilities of CHBAH, as well as PHC clinics in Soweto 
(Table 1). Thrombocytopenia was most commonly encountered in 
the haematology/oncology wards/clinic, in the intensive care units 
(ICUs) and among medical and neonatal inpatients, where the TP 
rates were 34.4%, 20.5%, 18.7% and 16.5%, respectively. Conversely, 
thrombocytopenia was least frequent in patients seen in non-
haematology/oncology outpatient (TP 1.7%) and PHC clinic facilities 
(TP 1.4%) (Table 1).
Causes of thrombocytopenia identified
Fifteen of the original samples with thrombocytopenia were found 
to be repeat specimens collected from the same patient on the 
same day, and these were excluded from further analysis. For the 
remaining 366 patients, a cause for the thrombocytopenia was 
apparent from the laboratory records in 229 (62.6%), unclear in 95 
(26.0%) and completely unknown in 42 (11.5%). Chemotherapy and 
sepsis together comprised >40% of the causes identified. Spurious 
thrombocytopenia, disseminated tuberculosis involving the bone 
marrow (BMTB), aplastic anaemia, ITP and a malignant marrow 
infiltration each accounted for 5 - 10% of the causes, while malaria, 
TTP, HIV effect and liver disease were each present in <5% of cases 
(Table 2).
Table 1. Patient epidemiological data, location and TP
Platelet count >100 × 109/L
(N1 = 4 075)
n (%)
Platelet count <100 × 109/L
(N2 = 381)
n (%)
TP
N2/(N1 + N2) (%) p-value¶
Age (years), mean (SD) 37.6 (0.6)* 30.6 ( 2.1)† N/A <0.0001
WCC (× 109/L), mean (SD) 8.32 (0.18) 9.77 (3.5) N/A 0.019
Hb (g/dL), mean (SD) 11.8 (0.1) 9.8 (0.3) N/A <0.0001
All patients - - 381/4 456 (8.6) N/A
Medical 479 (11.8) 110 (28.9) 110/589 (18.7) <0.0001
Surgical 493 (12.1) 26 (6.8) 26/519 (5.0) 0.002
Obstetrics/gynaecology 252 (6.2) 19 (5.0) 19/ 271 (7.0) 0.35
Haematology/oncology 168 (4.1) 88 (23.1) 88/256 (34.4) <0.0001
Paediatrics‡ 186 (4.6) 15 (3.9) 15/201 (7.5) 0.28
Neonatal wards 129(3.2) 23 (6.3) 23/152 (16.5) 0.0005
ICU§ 159 (3.9) 41 (10.8) 41/200 (20.5) <0.0001
Casualty 234 (5.7) 10 (2.6) 10/244 (4.1) 0.013
Miscellaneous outpatient clinics 956 (23.5) 17 (4.4) 17/973 (1.7) <0.0001
PHC clinics 824 (20.2) 12 (3.1) 12/836 (1.4) <0.0001
WCC = white cell count; Hb = haemoglobin value; N/A= not applicable. 
*N=4 006.
†N=378. 
‡Excluding neonates, paediatric oncology and ICU.
§Includes maternity high-care and coronary care units.
¶Statistically significant results are shown in bold.
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HIV test results were available in 261 (71.3%) of 
the patients with a low platelet count, of whom 
just under half tested positive. BMTB was 
significantly more prevalent among the HIV-
positive patients than among those who were 
negative (Table 2), while thrombocytopenia due 
to aplastic anaemia and a malignant marrow 
infiltrate were seen more often in HIV-negative 
patients. All patients who had BMTB were HIV-
positive, with evidence of AIDS in all those in 
whom a CD4 count was available.
Hepatitis B and C serology was performed 
in 84 (23.0%) and 73 (20.0%) of the 366 
patients, respectively. Of these, 11/84 (13.1%) 
tested positive for hepatitis B surface antigen 
and 4/73 (5.5%) for hepatitis C. The cause of 
the thrombocytopenia was evident in 12/15 
(80.0%) of the patients with either hepatitis B 
or C; of these, 5/12 (41.7%) had evidence of 
liver disease, 2/12 (16.7%) and 2/12 (16.7%) 
had BMTB or a malignancy, respectively, and 
only 1/12 (8.3%) had ITP. Of interest was that 
none of the patients with aplastic anaemia was 
proven to be either hepatitis B- or C-positive.
Laboratory work-up
Peripheral blood smear review was per-
formed in 292 patients (79.8%), and 102 
(27.9%) had had a recent bone marrow 
aspirate and trephine biopsy. Cultures of a 
variety of specimen types were performed 
in 232 patients (63.4%), of whom 33 
(14.2%) had documented evidence of bac-
terial infection. Coagulation testing was 
requested in 150 patients (41.0%) and 
revealed some evidence of a coagulopathy 
in 35 (23.3%) of the tested patients. Of note 
was that coagulation testing was performed 
in only 48.6% of patients with documented 
sepsis (excluding neonatal patients). 
Multivariate logistic regression revealed 
significant independent associations 
between the presence of a coagulopathy 
and sepsis (OR 4.5 (95% CI 3.9 - 5.0); 
p=0.006), liver disease (OR 34.3 (95% CI 
33.0 - 35.5); p=0.005) and BMTB (OR 5.3 
(CI 4.7 - 6.0); p=0.017).
Adequacy of laboratory work-up
Laboratory work-up was judged to be 
adequate in 181 patients (49.5%), partially 
adequate in 143 (39.1%) and completely 
inadequate in 42 (11.5%). Investigation was 
most complete in neonatal and haematology/
oncology patients, where the work-up was 
adequate in >80% of cases. Completely 
inadequate work-up very seldom occurred 
in paediatric and ICU patients (<1% and 
2.7%, respectively). Work-up was generally 
suboptimal in surgical inpatients and those 
seen in non-haematology outpatient clinics, 
both of which had an inadequate work-up 
in >25% of cases. Work-up was very poor 
in patients seen in PHC clinics, with >90% 
having a completely inadequate work-up 
(Table 3). Reasons for work-up inadequacy 
varied, but important contributors included 
omission of peripheral blood smear review 
in 70 patients (37.8% of those with an 
incomplete work-up). This was most 
striking in patients seen in PHC clinics, 
where peripheral smear review was 
performed in only one patient. There was 
failure to screen for a coagulopathy in 
118 (63.7%) of the 185 patients with an 
incomplete work-up, with a full DIC screen 
performed in only eight (4.3%) of these 
patients (Table 3). Among the patients with 
an incomplete work-up, the omission of a 
coagulopathy screen was relatively more 
common in medical patients, while testing 
in ICU, surgical or haematology/oncology 
patients was generally carried out more 
frequently.
Discussion
This study reveals that thrombocytopenia 
is common among hospitalised patients in 
the Johannesburg academic state sector, 
particularly among haematology/oncology 
patients, neonatal inpatients and patients 
admitted to medical wards or ICUs. In 
contrast, a low platelet count is unusual 
in patients seen in PHC clinics or non-
haematology/oncology outpatient clinics, 
being present in only 1 - 2% of the FBCs 
received from these locations. However, since 
>40% of the FBCs processed at the CHBAH 
laboratory were received from outpatient 
or PHC clinics, patients attending these 
facilities comprised a relatively substantial 
proportion of all cases of thrombocytopenia.
Although the study is somewhat 
compromised by a paucity of clinical 
information, the critical role of laboratory 
testing allowed for determination of the 
cause of the low platelet count in 62% 
of the patients based on a review of 
laboratory records, as well as for evaluation 
of the adequacy of the laboratory work-up. 
Since CHBAH is a haematology referral 
centre, chemotherapy effect and primary 
haematological causes of thrombocytopenia 
(such as aplastic anaemia and malignant 
marrow infiltration) were prominent in this 
cohort, collectively comprising some 40% 
of the low platelet counts seen. Although 
malaria and TTP are often emphasised as 
Table 2. Causes of thrombocytopenia identified
Total cohort with 
a cause identified 
(N=229)
n (%)
Causes identified in patients with 
known HIV status
HIV-positive (N=83) v. HIV 
negative (N=99), n (%); p-value‡
Chemotherapy* 47 (20.5) 15 (18.1) v. 26 (26.3);
0.13
Sepsis 56 (24.5) 21 (25.3) v. 16 (16.2);
0.09
Spurious thrombocytopenia 13 (5.7) 4 (4.8) v. 1 (1.0);
0.13
TTP 4 (1.7) 3 (3.6) v. 1 (1.0);
0.25
Malaria 7 (3.1) 0 (0.0) v. 3 (3.0);
0.16
Malignant marrow infiltrate 17 (7.4) 3 (4.8) v. 14 (14.1);
0.013
ITP 19 (8.3) 8 (9.6) v. 11 (11.1);
0.5
Aplastic anaemia 22 (9.6) 3 (3.6) v. 19 (19.2);
0.0009
BMTB 16 (7.0) 16 (19.3) v. 0 (0.0);
<0.0001
HIV effect† 6 (2.6) 6 (7.2) v. 0 (0.0);
0.008
Liver disease  8 (3.5) 2 (2.4) v. 2 (2.0);
0.6
*Chemotherapy was used in HIV-positive patients, predominantly in the treatment of high-grade lymphoma.
†These patients had HIV-related bone marrow changes without any other cause for the low platelet count identified.
‡Statistically significant results are shown in bold.
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causes of thrombocytopenia, they proved comparatively rare, each 
accounting for <5% of the thrombocytopenic samples. Among 
the HIV-positive patients, common causes of thrombocytopenia 
included chemotherapy for high-grade lymphomas, BMTB and 
sepsis. Interestingly, although both ITP and TTP are well-described 
causes of HIV-associated thrombocytopenia, the prevalence rates 
of these diseases did not differ between HIV-positive and negative 
patients in this cohort, possibly in part because of small sample 
sizes.
HIV status was documented in approximately 70% of the 
patients, of whom just under half were HIV-positive. This is not 
surprising given the high background prevalence of HIV in the SA 
population, as well as the strong association between HIV infection 
and thrombocytopenia. In contrast, hepatitis B and C positivity 
were uncommon, and presented most frequently in patients with 
thrombocytopenia attributable to chronic liver disease. However, as 
most patients were not tested for hepatitis B and C, their roles in the 
pathogenesis of thrombocytopenia in this setting remain unclear. 
Nonetheless, we noted with interest that none of the patients with 
aplastic anaemia had viral hepatitis, and only one patient with ITP 
tested seropositive for hepatitis C.
Among the hospitalised patients, laboratory work-up was judged 
to be good in the majority of paediatric and ICU patients as well as 
in neonates and haematology/oncology patients. In contrast, work-
up was generally suboptimal in patients seen in outpatient clinics 
or admitted to surgical wards, and was very poor in patients seen 
at PHC clinics. While it is possible that some of the latter patients 
might have been transferred to an alternative hospital for work-up, 
this finding could reflect a deficiency in the clinical approach to 
thrombocytopenia among healthcare workers at primary facilities. 
Further studies in this regard would be of interest. Of concern is 
that among the common reasons for the work-up being judged 
incomplete was the absence of peripheral blood smear review, which 
was omitted in ~20% of patients. As it is a laboratory policy to review a 
blood film in samples with a platelet count <100 × 109/L, this finding 
highlights deficiencies in both the clinical and laboratory services, 
possibly as a result of the pressures of high case volumes and a skills 
shortage in both these settings. Also of note was that investigation 
for coagulopathy was poor, being requested in just over 40% of all 
patients. This is of particular concern in view of the fact that DIC 
is an important cause for thrombocytopenia in patients with sepsis, 
the prevalence of which was high in our cohort. DIC is associated 
with a high mortality rate and may necessitate fresh-frozen plasma 
and/or cryoprecipitate infusion. It is therefore important that a 
coagulopathy screen (including an INR, PTT, fibrinogen level and 
D-dimer assay) be performed in all patients with thrombocytopenia 
in the presence of any of its possible precipitants, including 
sepsis.[5,6] Not unexpectedly, we found an independent association 
between the presence of laboratory evidence of a coagulopathy and 
the presence of both chronic liver disease and sepsis. Of interest 
was that an association was also evident in patients with BMTB, 
suggesting that a consumptive coagulopathy (such as DIC) is a 
likely contributor to the low platelet count frequently seen in these 
patients. This is supported by the normal megakaryocyte numbers 
Table 3. Analysis of adequacy of laboratory work-up
Completely 
inadequate work-up 
frequency 
 n/N (%); p-value*
Adequate work-up 
frequency
n/N (%); p-value
Frequency of coagulation 
testing omission among 
patients with an incomplete 
work-up
n/N (%); p-value
Frequency of peripheral 
smear review omission 
among patients with an 
incomplete work-up
n/N (%); p-value
All patients 42/366 (11.5);
N/A
181/366 (49.5);
N/A
118/185 (63.8);
N/A
70/185 (37.8);
N/A
Medical 9/107 (8.4);
0.16
41/107 (38.3);
0.004
40/65 (61.5);
0.38
14/65 (21.5);
0.0005
Surgical 6/23 (26.1);
0.036
8/23 (34.8);
0.11
2/15 (13.3);
<0.0001
7/15 (46.7);
0.32
Obstetrics/gynaecology 2/19 (10.5);
0.62
4/19 (21.0);
0.009
7/15 (46.7);
0.12
4/15 (26.7);
0 .26
Haematology/oncology (adult and 
paediatric)
1/86 (1.2)
0.0001
74/86 (86.0);
<0.0001
8/12 (33.3);
0.027
0/12 (0.0);
0.026
Paediatrics† 0/13 (0.0);
0.2
8/13 (61.5);
0.27
4/5 (80.0);
0.4
1/5 (20.0);
0.37
Neonatal wards 0/23 (0.0);
0.055
23/23 (100.0);
<0.0001 
N/A N/A
ICU‡ 1/37 (2.7);
0.055
12/37 (32.4);
0.02
10/25 (40.0);
0.008
14/25 (56.0);
0.26
Miscellaneous outpatient clinics 5/16 (31.3);
0.026
6/16 (37.5);
0.24
8/10 (80.0);
0.23
5/10 (50.0);
0.31
PHC clinics 11/12 (91.7);
<0.0001
1/12 (8.3);
0.003
5/11 ( 45.6)
0.16
11/11 (100.0)
<0.0001
N/A= not applicable.
*p-values are derived from Fisher’s exact analysis of each group v. the rest of the cohort. Statistically significant results are shown in bold.
†Excluding neonates, paediatric oncology and ICU.
‡Includes maternity high-care and coronary care units.
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as well as the raised immature platelet fraction (a parameter that 
reflects increased platelet production) seen in many patients with 
BMTB.[7]
Conclusion
Thrombocytopenia was found to be common in hospitalised patients 
in the academic state sector in Johannesburg, but relatively rare in the 
outpatient setting. Chemotherapy and sepsis were identified as the 
commonest causes, irrespective of HIV status. The quality of laboratory 
work-up was found to be poorest in the PHC clinic sector, and varied 
between disciplines within the hospital setting. The findings emphasise 
the need for a standardised approach to thrombocytopenia investigation 
and increased awareness on the part of clinicians, most particularly 
among PHC providers and those working in surgical disciplines.
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